Last reviewed · How we verify

Transplanted organ rejection — Treatment Landscape & Competitive Intelligence

Transplanted organ rejection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Transplanted organ rejection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Prograf TACROLIMUS Astellas Pharma Calcineurin Inhibitor Immunosuppressant Interferon gamma 1994-01-01
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01
Solu-Cortef hydrocortisone succinate Pfizer Corticosteroid Glucocorticoid receptor 1955-01-01
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01
Cortifoam HYDROCORTISONE ACETATE Pfizer Corticosteroid Corticosteroid-binding globulin 1951-01-01
prednison prednison Wen Zhang Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor
Cortisol Cortisol University of Zurich Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 4 drugs in Transplanted organ rejection
  2. Pfizer · 2 drugs in Transplanted organ rejection
  3. Generic (originally Schering) · 2 drugs in Transplanted organ rejection
  4. Generic (originally Merck/Upjohn) · 1 drug in Transplanted organ rejection
  5. Generic (originally Upjohn/Pfizer) · 1 drug in Transplanted organ rejection
  6. Hannover Medical School · 1 drug in Transplanted organ rejection
  7. Leiden University Medical Center · 1 drug in Transplanted organ rejection
  8. University of Zurich · 1 drug in Transplanted organ rejection
  9. Wen Zhang · 1 drug in Transplanted organ rejection
  10. Astellas Pharma · 1 drug in Transplanted organ rejection
  11. Generic (originally Merck) · 1 drug in Transplanted organ rejection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Transplanted organ rejection:

Cite this brief

Drug Landscape (2026). Transplanted organ rejection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/transplanted-organ-rejection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing